Background. In this study (part of the global T.E.S.T. program) was evaluated the in vitro activity of tigecycline, member of a new class of antimicrobial agents, the glycylcyclines, against clinical isolates collected in Italy. 
INTRODUCTION
Tigecycline is a first-in-class of expanded broadspectrum glycylcycline. It inhibits bacterial protein synthesis by binding to the 30s ribosomial subunit, but with five times highter affinity than tetracyclines (2) . This new drugs was approved for use in Europe in 2006 for complicated skin and soft-tissue and intra-abdominal infections (http://www.emea.europa.eu/humandocs/Humans /EPAR/tygacil/tygacil.htm). In vitro studies demonstrate that it has good activity against many commonly encountered respiratory bacteria, including multiple resistant Gram positive, Gram negative, anaerobic, as well as multidrug-resistant (MDR) pathogens such methicillinresistant S. aureus (MRSA) and S. epidermidis (MRSE), vancomycin-resistant Enterococcus spp. (VRE), penicillin-resistant S. pneumoniae (PRSP) and β-lactamase producing H. influenzae (3) . Tygeciclyne inhibits bacterial protein biosynthesis blocking the attachment of amino-acyl tRNA to the A site of the ribosome and preventing the elongation of peptide chains (6) . The drug mantaines its activity even in presence of efflux pumps (encoded by tetA-tetD and tetK genes) and ribosomal protection (tetM) mechanisms that otherwise confer tetracycline resistance. Tigecycline appears to overcame these mechanisms of resistance because of steric hindrance due to the addition of a large substituent on the D ring at the 9th position of the tetracycline molecule (7, 13) . This study is part of the larger global Tigecycline Evaluation and Surveillance Trials (T.E.S.T.) program and was undertaken to document the in vitro activity of tigecycline against clinical isolates collected in Northen Italy from in-patient and outpatient populations.
MATERIALS AND METHODS
A total of 194 clinical isolates were collected and identified to the species level in our Institution during 2010. Isolates were collected from both inpatients and outpatients with a documented infections in which the isolate collected was identified as the probable causative organism according to institutional criteria. Only one isolate per patient was accepted into the study. Minimum inhibitory concentrations (MICs) of the antimicrobial agents were determined by the Clinical and Laboratory Standards Institute(CLSI) (11) recommended broth microdilution testing method. Overnight cultures of bacteria were diluted to give a final concentration of approximately 5x10 5 cells/ml. Samples were then added to equivalent volumes of the various concentration of antibiotics distributed on a microplate and prepared from serial twofold dilutions. hours of incubation at 37°C, the concentrations of drugs that prevented visible growth were recorded as the MICs. Tigecycline was supplied by Wyeth Pharmaceuticals (Collegeville, PA, USA). All other agents were supplied by the panel manufac (11) and recent US Food and Drug Administration guidelines for tigecycline (Tygacil, Product Insert. Wyeth Pharmaceuticals, Inc., Philadelphia, PA, USA, 2005) were followed. As no interpretative criterion for tigecycline with Acinetobacter baumannii has been established, Clinical and laboratory Standards Institute interpretative criteria for Enterobacteriaceae were used for A. baumannii, as had been reported in previous literature (1, 17 
RESULTS
The largest number of isolates was collected from in-patients population (medicine, surgery, ICU, nursing home\rehabilitation, renal, infectious diseases, paediatrics and obstetrics), only 35% of strains derived from community acquired infections (Table 1 (Table 4) . Tigecycline demonstrated a good inhibitory activity against A. baumannii (MIC 50 1mg\l and MIC 90 2mg\l) even on multi-drug resistant strain, with the exception of a single isolate which showed a MIC value corresponding to 8mg\l. Such result is consistent with recent reports of emergence of tigecycline-resistant A. baumannii after tigecycline therapy (1, 14) (Table  4) . In vitro tigecycline's activity on A. baumannii was superior to beta-lactams, beta-lactams/beta-lactamase inhibitor combinations, cephalosporins, aminoglycosides and levofloxacin. Tigecycline demonstrate excellent inhibitory activity against H. influenzae (MIC 50 and MIC 90 0.25mg\l), included β-lactamase-producers strains (Table 4) . Against Gram positive isolates (Table 5) , tigecycline shown an excellent activity against Enterococcus spp. The drug presented MIC 90 of 0.25 mg\l, regardless of susceptibility to vancomycin. This value was the lowest of all comparative agents, in particular was several folds lower than linezolid, minocycline and levofloxacin. The drug has shown a potent inhibitory activity against S. aureus regardless of methicillin-resistant phenotype. Tigecycline, with MIC 50 and MIC 90 values of 0.25 and 0.5 mg/l, respectively, demonstrated in vitro activity comparable to vancomycin and greater than linezolid and levofloxacin against MRSA. In MSSA the MIC 50 and MIC 90 value was 0.25 mg/l and 0.5 mg/l respectively. Tigecycline demonstrated potent inhibitory activity against S. agalactiae and S. pneumoniae (Table  6) , even in penicillin-resistant strains, with MIC 90 values Յ1mg\l.
DISCUSSION
Resistance to currently available antibiotics and incidence of infection due to multidrug-resistant bacteria has dramatically increased worldwide during the last twenty years. In presence of a serious infection, appropriate empirical antibiotic therapy can be life-saving and the choice of an antimicrobial to which the pathogens are susceptible may be critical. For these reasons, the development of new antimicrobial agents with expanded antibacterial spectrum (increased activity against Gram negative as well as Gram positive microrganisms) is more urgent than ever (5, 18). Tigecycline's in vitro activity was comparable to or greater than most commonly prescribed antimicrobial against important clinical pathogens. Tigecycline, for example, demonstrated on methicillin-resistant S. aureus (MRSA) in vitro activity comparable to vancomycin, the antimicrobial agents currently used for the treatment of serious staphylococcal infections and exhibits greater activity to linezolid against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium (VRE). This promising compound may be usefull even in the treatment of serious infections caused by resistant Gram negative strains with limited therapeutic options. Tigecycline has shown to be highly effective agains E. coli and Klebsiella spp. A. baumannii is a problematic pathogen, particularly in ICUs. The results from TEST reveal that no antimicrobial agents tested was active against A. baumanni. Tigecycline was the only agent that shown a good inhibitory activity against A. baumannii that are commonly associated with serious nosocomial infections. Resistance of Acinetobacter to cephalosporins, aminoglycosides and quinolones is widespread with an increasing of multi-drug resistance (9, 8) . Tigecycline is a potent antimicrobial agent even against the infections due to this important pathogen. The drug demonstrated a limited activity, similar to other tetracyclines, only against P. aeruginosa. The in vitro activity of tigecycline observed in this study suggests that this drug is a suitable antimicrobial agent for empiric treatment of serious infections sustained by some of the commonly encountered pathogens. Tigecycline is available as parenteral agent, has linear pharmacokinetics, long terminal half-life and is extensively distributed in tissues (15) . Some interesting applications for this drug may be in surgical wound infections (particularly following abdominal surgery), and as alternative therapeutic agent in patient with serious allergies to β-lactam antibiotics (10) . Results from Phase III clinical studies in the treatment of complicated skin and skin structure infection (cSSSI) and complicated intra-abdominal infection (cIAI) have demonstrated the potential of tigecycline used as monotherapy for the treatment of this infections: the drug showed equivalence to imipenem in cIAI and to vancomycin plus aztreonam in cSSSI (12, 16, 4, 19) . The in vitro and in vivo studies points out that, tigecycline, with an expanded broad-spectrum antimicrobic activity against Gram positive and negative bacteria, offers a new alternative for the treatment of infections caused by clinically relevant pathogens in which the emergence of resistance to previously active antibiotics has created to the physicians limitations in therapeutic options. 
